- Efficacy, safety and tolerability of the preservative-free (PF) fixed combination (FC) of tafluprost 0.0015% and timolol 0.5% (once daily) were compared to those of the individual components (PF tafluprost 0.0015% once daily and PF timolol 0.5% twice daily).
- Previous users of timolol (TS) and previous users of prostaglandin analogues (PS) were investigated using a stratified, double-masked, randomized, multicenter phase III clinical trial.
- PF FC tafluprost and timolol provided a substantial and significant intraocular pressure (IOP) reduction in both strata.
- The IOP reduction was superior to both tafluprost 0.0015% and timolol 0.5% when given as monotherapies.
- Overall, the study treatments were safe and well tolerated.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Santen Oy, Tampere, Finland. Medical writing assistance for this study was provided by Friedemann Kimmich (eyecons, Pfinztal, Germany; funded by Santen Oy, Tampere, Finland). For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. 